A Novel Small Molecule FL118 That Selectively Inhibits Survivin, Mcl-1, XIAP and cIAP2 in a p53-Independent Manner, Shows Superior Antitumor Activity

Overview of attention for article published in PLOS ONE, September 2012

Altmetric Badge

About this Attention Score

In the top 25% of all research outputs scored by Altmetric
High Attention Score compared to outputs of the same age (90th percentile)
High Attention Score compared to outputs of the same age and source (87th percentile)

Mentioned by

twitter: 2 X users

patent: 9 patents

Readers on

mendeley: 59 Mendeley

So far, Altmetric has seen 9 patents that reference this research output.

Antibody, antibody-drug conjugate thereof and use thereof

Grant US-12742009-B2

United States of America

22 Sep 2026

ANTIBODY, AND DRUG CONJUGATE AND USE THEREOF

Application WO-2023160651-A1

World Intellectual Property Organisation (WIPO)

31 Aug 2023

ANTIBODY, ANTIBODY-DRUG CONJUGATE THEREOF AND USE THEREOF

Application WO-2023046202-A1

World Intellectual Property Organisation (WIPO)

30 Mar 2023

Use of the FL118 core chemical structure platform to generate FL118 derivatives for…

Grant US-11084828-B2

United States of America

10 Aug 2021

This page shows the most recent patents that mention this research output. Click here to find out how to access more activity, including 5 additional patents.